Literature DB >> 87620

Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

G U Corsini, M Del Zompo, G L Gessa, A Mangoni.   

Abstract

Apomorphine in combination with a peripheral dopamine receptor blocker (domeperidone) was administered to four parkinsonian patients in a double-blind placebo-controlled study. The therapeutic efficacy of apomorphine was not reduced by domperidone, while nausea, drowsiness, sedation, and arterial hypotension were prevented. Combination of domperidone with dopamine agonists may result in more effective treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87620     DOI: 10.1016/s0140-6736(79)91725-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.

Authors:  M Merello; Z Pirtosek; S Bishop; A J Lees
Journal:  Clin Auton Res       Date:  1992-08       Impact factor: 4.435

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 3.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

4.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

Authors:  U Sabatini; O Rascol; P Celsis; G Houin; A Rascol; J P Marc-Vergnes; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

5.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  K R Chaudhuri; C Clough
Journal:  BMJ       Date:  1998-02-28

6.  A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.

Authors:  Hilary L Tyne; Jan Parsons; Ann Sinnott; Susan H Fox; Nicholas A Fletcher; Malcolm J Steiger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

7.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

8.  Domperidone antagonizes bromoergocriptine--induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women.

Authors:  C Nappi; G Colace; G F Di Renzo; M Taglialatela; S Amoroso; L Annunziato; U Montemagno
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.